Electroacupuncture inhibits weight gain in diet-induced obese rats by activating hypothalamicLKB1-AMPK signaling by unknown
Xu et al. BMC Complementary and Alternative Medicine  (2015) 15:147 
DOI 10.1186/s12906-015-0667-7RESEARCH ARTICLE Open AccessElectroacupuncture inhibits weight gain in
diet-induced obese rats by activating
hypothalamicLKB1-AMPK signaling
Jing Xu1†, Liang Chen1,3†, Lewei Tang1,3, Le Chang1, Si Liu1, Jinfeng Tan1, Yinglong Chen2, Yulan Ren1,
Fanrong Liang1* and Jin Cui2*Abstract
Background: Electroacupuncture (EA) is reported to be an effective treatment for obesity, but its mechanism is
unclear. This study aimed to investigate the relationship between hypothalamic LKB1-AMPK-ACC signaling and EA.
Methods: Fifty male Sprague–Dawley rats were divided into two groups fed either chow (chow-fed group) or
high-fat diet (HF group). After 4 weeks of feeding, obese rats in the HF group (defined as weighing 20 % or more
than rats in the chow-fed group) were randomly allocated into an EA or Diet-induced obesity (DIO) group. The EA
group was given EA on bilateral ST25–ST36 for 4 weeks, while the DIO group received no further intervention. Body
weight of the chow-fed, DIO, and EA groups were measured weekly. mRNA and protein levels of the hypothalamic
LKB1-AMPK-ACC signaling pathway were detected using real-time (RT)-PCR and western blot, respectively.
Results: After 4 weeks of EA treatment, the weight growth trend of rats in the EA group was inhibited compared
with those in the DIO group. RT-PCR and western blotting showed that EA upregulated the transcription of
Adenosine 5′-monophosphate -activated protein kinase α2 (AMPKα2), promoted protein expression of Liver kinase
B1 (LKB1) and AMPKα1, and inhibited acetyl-CoA carboxylase (ACC) protein expression in the hypothalamus.
Conclusions: This study suggests that hypothalamic LKB1-AMPK-ACC signaling plays an important role in EA
treatment for obesity.
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Obesity is a worldwide public health problem, and can
lead to diseases like coronary heart disease, diabetes, and
some cancers [1]. Several investigations into curbing the
increasing obese population have been conducted, but
there are few effective pharmacological treatments. Only
three drugs have been approved by the US Food and
Drug Administration for long-term obesity treatment,
namely lorcaserin (Belviq), phentermine plus topiramate
(Qsymia), and orlistat (Xenical, Alli) [2].* Correspondence: acuresearch@126.com; arlene0411@163.com
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creativecommons.org/publicdomain/zero/1.0/Acupuncture is one of the most popular alternative
therapies, and it has been used to treat obesity for thou-
sands of years. Electroacupuncture (EA) is a common
form of acupuncture in which an electric current is
passed through acupuncture needles. The parameters of
the EA can be precisely characterized, so it is reprodu-
cible, and data suggest that EA may be more effective
than manual acupuncture [3]. Recent systematic reviews
indicate that EA is an effective treatment for obesity [4].
However, the mechanism of EA on obesity needs further
investigation. There is evidence indicating that EA may
suppress appetite to control weight. The possible mecha-
nisms underlying the effect of EA focus on the hypothal-
amus [5, 6].
The hypothalamus regulates food intake and energy bal-
ance. Hypothalamic adenosine 5′ monophosphate-activated
protein kinase (AMPK) is recognized as a nutrient anddistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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tor of appetite [7, 8]. Liver kinase B1 (LKB1) is the major
upstream kinase in the AMPK cascade. LKB1 is constitu-
tively active and phosphorylates AMPK at Thr172 of the α
subunit [9–11]. AMPK activation is abolished in cells lack-
ing LKB1 expression or in rodents after deletion of LKB1
[12, 13]. One mechanism by which AMPK regulates lipid
metabolism is via phosphorylation and inactivation of
acetyl-CoA carboxylase (ACC), an important rate-limiting
enzyme for the synthesis of malonyl-CoA [14]. ACC is both
a precursor for fatty acid biosynthesis and an inhibitor of
long-chain fatty acyl-CoA transport to mitochondria for β-
oxidation [15]. Knockdown/knockout of ACC1 and ACC2
was reported to cause continuous fatty acid oxidation, in-
creased energy expenditure, and reduced fat mass [16, 17].
Several studies have studied the relationship between
EA and AMPK. Tominaga et al. [18] suggested that re-
peated EA therapy is capable of improving diet-induced
insulin resistance, possibly via AMPK signaling activa-
tion in skeletal muscle. Immediately after EA stimula-
tion, phospho-AMPKα (Thr172) was significantly higher
in animals receiving EA than control animals. Kim et al.
[19] showed that levels of AMPK gene expression in the
rat hypothalamus determine individual differences in the
sensitivity to EA-induced analgesia. However, there has
been no thorough investigation into EA and AMPK in
the hypothalamus.
Based on a diet-induced obesity (DIO) rat model, we ob-
served whether EA can inhibit weight gain in rats given an
HF diet. We also investigated the role of hypothalamic
LKB1-AMPK-ACC signaling in the obesity pathology and
EA treatment mechanism.
Methods
Animals and experimental protocol
54-week-old male Sprague–Dawley rats (80–100 g) were
obtained from Dossy Experimental Animals Company
(Chengdu, China). Animals were housed in a facility
with ambient temperature (22 ± 2 °C) and maintained in
12/12 h light–dark cycles (light on from 07:00 to 19:00).
To acclimatize to the new environment, all rats were fed
with standard laboratory chow and water available ad
libitum during the first week of the experiment. Animals
were randomly divided into two groups: a chow-fed
group and a high-fat (HF) group. The chow-fed group
(n = 13) was given standard laboratory chow (Dossy Ex-
perimental Animals Company, 3.80 kcal/g), composed of
5 % fat, 55 % carbohydrates, 22 % protein, 7 % ash, and
5 % fiber. The HF group (n = 35) was given an HF diet
(4.72 kcal/g) composed of 22 % fat, 39 % carbohydrate,
23.7 % protein, 4 % ash, and 3 % fiber. HF food was
made in the authors’ laboratory. Each 100 g of HF food
was composed of basic feed (57.5 g), egg yolk powder
(11.79 g), lard (10 g), pig bile salt (0.2 g), casein (7 g),milk power (13 g), salt (0.085 g), and yeast powder
(0.425 g). Body weight was monitored once every week
at 09:00.
After feeding for 4 weeks, 24 rats fed the HF diet had
gained weight 20 % or more above the average weights
of rats in the chow-fed group, and were defined as
obese. These rats were then randomly allocated into an
EA group receiving EA stimulation for four weeks, and a
DIO group receiving no further treatment, with 12 rats
in each group. The EA, DIO, and chow-fed groups were
housed individually, and fed with their corresponding di-
ets. Food intake and body weight were measured daily
for 4 weeks. Hypothalami were collected at the end of
the study. The study was approved by the Institutional
Animal Care and Use Committee of Chengdu University
of Traditional Chinese Medicine and all procedures were
conducted in accordance with Animal Experiments
Guidelines and Animal Care of Chinese Academy of
Sciences.
EA treatment
Rats in the three groups were consciously restrained in a
plastic holder. The EA group was treated with EA a bi-
lateral Tianshu (ST25) and Zusanli (ST36) acupoints for
20 min from 8:00 to 12:00 a.m., once a day, 6 days per
week, for four weeks in total. The needles used were
disposable sterile stainless steel needles with diameter
0.30 mm and length 25 mm (Suzhou Hua Tuo Medical
Instruments Co. Ltd, Suzhou, China). Points were chosen
based on the standards for rats, as recorded in Experimen-
tal Acupuncture and Moxibustion [20]. Tianshu (ST25) is
located 5 mm lateral to the navel (5 mm lateral to the
intersection between the upper 2/3 and the lower 1/3 in
the line between xiphoid process and pubic symphysis
upper border). Zusanli (ST36) is located between the tibia
and fibula at approximately 5 mm lateral and 5 mm lower
to the anterior tubercle of the tibia. The acupoints were
stimulated with a continuous-wave electrical stimulus with
an intensity of 2 mA and frequency of 3 Hz for 20 min to
produce slight twitches in the limbs. The G6805-II EA
instrument (No. 20,101,014, Qingdao Xinsheng Ltd.,
Qingdao, China) was used. Rats in the chow-fed and
DIO groups were restrained for 20 min without EA
stimulation. The rats did not show any pain or discom-
fort during the treatments.
All experimental rats were fasted for 10 h after the last
intervention was given, and their body weight was re-
corded (g). Under 20 % urethane (0.8 g/kg) anesthesia,
rats were euthanized. Then, hypothalamic tissues were
dissected for further tests.
Western blot analysis
Hypothalami were dissected using the optic chiasm as a
rostral landmark, and the mammillary bodies caudally to
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frozen in liquid nitrogen. Tissues were homogenized in
ice-cold lysis buffer containing 0.1 % SDS, 10 mM Tris–
HCl (pH 7.4), 1 % Triton X-100, 1 mM MgCl2, and 1 %
NP-40. Homogenates were centrifuged at 10,000 g for
10 min at 4 °C, supernatants were removed, and ali-
quots were snap-frozen in liquid nitrogen. Hypothal-
amus lysate (40 μl) was subjected to sodium dodecyl
sulfate - polyacrylamide gel electrophoresis (SDS-PAGE)
on 6 % polyacrylamide gels and electrotransferred on a
nitrocellulose membrane (Millipore, Massachusetts, USA).
Membranes were blocked for 1.5 h in bovine lacto trans-
fer technique optimizer hybridization solution (50 mM
Tris [pH 8.0], 2 mM CaCl2, 0.01 % Antifoam A, 0.02 %
NaN3, and 0.05 % Tween 20) containing 5 % skim milk.
Membranes were then probed at 4 °C in Tris-buffered
Saline and Tween 20 (TBST) overnight with the appro-
priate dilution of the indicated antibodies against LKB1
(Abcam, Cambridge, UK), ACC (Abcam, Cambridge, UK),
p-AMPKα1 (Abcam, Cambridge, UK), AMPKα1 (Saierbio,
Tianjin, China), p-AMPKα2 (Abcam, Cambridge, UK),
AMPKα2 (Saierbio, Tianjin, China), and GAPDH (Saierbio,
Tianjin, China).
Detection of proteins was performed using horseradish
peroxidase—conjugated secondary antibodies (goat anti-
rabbit antibody, Saierbio, Tianjin, China) and an enhanced
chemiluminescence reagent (Western Lightning-ECL;
Perkin Elmer, Waltham, MA, USA), then exposed to film.
The intensity of protein bands was quantitated using Lab
Works 4.0 software (UVP Inc., Upland, CA, USA).
RNA extraction and real-time PCR
Rat tissue was isolated, frozen in liquid nitrogen, and
stored at −80 °C until extraction. Total RNA was ex-
tracted from about 100 mg of hypothalamus using TRIzol
(Invitrogen, Carlsbad, CA, USA), as described by the
manufacturer. The purity and concentration of isolated
RNA was determined by measuring absorbance at 260











GAPDH R AGGGGCCATCCACAGTCTTCGermany). An aliquot (5 μg) of extracted RNA was reverse
transcribed into first-strain complementary DNA (cDNA)
using an M-MLV RT reagent (Promega, Madison, WI,
USA). The following thermal cycling protocol was used
for reverse transcription: 42 °C for 30 min, and 70 °C for
10 min. Real-time PCR was performed with a Bio-Rad iQ5
thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA)
using SYBR Premix Ex Taq™ (Takara, Dalian, China).
Thermocycling was carried out in a final volume of 20 μl
containing 0.5 μl of the cDNA sample, 10 μl of SYBR
Green Mix (Takara), and 2 μl of primers (forward and re-
verse primers, 5 pmol/μl). The PCR protocol included ini-
tial denaturation of 4 min at 94 °C, followed by 40 cycles
of amplification for 30 s at 94 °C, 30 s at 50 °C, and 40 s at
72 °C. Triplicate samples were run for real-time PCR.
Relative expression was calculated as follows: density of
the product of respective target gene divided by that for
GAPDH from the same cDNA. Specific primers used for
PCR are listed in Table 1.Statistical analysis
All experimental data are expressed as means ± standard
deviations. Statistical analysis was performed by SPSS
Statistics for Windows, Version 20.0 (IBM, Armonk, NY,
USA) and one-way ANOVA for comparisons among
groups. For all analyses, P < 0.05 was considered to be
statistically significant.Results
EA inhibits weight gain from an HF diet
Figure 1a shows that rats in the HF-fed group gained
more body weight than those in the chow-fed over 4 weeks.
Differences in body weight were noticeable from 1 week,
but were significant after 4 weeks. 24 rats fed the HF diet
became obese (gained 20 % or more weight above the
average weight of rats in the chow-fed group), and were
separated into two groups at the end of 4 weeks. There











Fig. 1 Body weight changes before and after diet-induced obesity model establishment. (a) Body weight gain in high fat (HF) and chow-fed rats.
(b) Body weight gain in EA, diet-induced obesity (DIO), and chow-fed rats. (c) Body weight after 10-h fasting of electroacupuncture (EA), DIO, and
chow-fed rats. *P < 0.05, **P < 0.01, ***P < 0.001 EA vs. DIO; #P < 0.05, ##P < 0.01, ###P < 0.001, EA vs. chow; ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 DIO vs. chow
Xu et al. BMC Complementary and Alternative Medicine  (2015) 15:147 Page 4 of 9Figure 1b shows that EA treatment inhibits body
weight gain in rats fed an HF diet. The most significant
differences between the EA and DIO groups were ob-
served in the seventh week (P = 0.001), although the
body weights between the two groups were not signifi-
cantly different (5.49 % lower in the EA group, P =
0.129) at the end of the experiment. Figure 1c shows
that rats in the EA group had a significantly lower bodyweight compared with those in the DIO group after fast-
ing for 10 h (P = 0.027).
Effects of EA on hypothalamic AMPK signaling
Figure 2a shows that rats fed an HF diet had lower ex-
pression of LKB1 (P = 0.000), AMPKα1 (P = 0.020), and
AMPKα2 (P = 0.000), and significantly higher transcrip-
tion of ACC (P = 0.024) than rats in the chow-fed group.
Fig. 2 Effects of electroacupuncture on adenosine 5′-monophosphate-activated protein kinase signaling in hypothalamus. (a) mRNA levels of liver
kinase B1 (LKB1), acetyl-CoA carboxylase (ACC), Adenosine 5′-monophosphate -activated protein kinase (AMPK)α1, and AMPKα2 in each group.
(b) Quantization of protein levels in each blot by densitometry shown in (c). (c) Representative western blots in each group to show LKB1, ACC,
AMPKα1, and AMPKα2 protein content. *P < 0.05, **P < 0.01, ***P < 0.001 electroacupuncture (EA) vs. diet-induced obesity (DIO); #P < 0.05, ##P < 0.01,
###P < 0.001, EA vs. chow; ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 DIO vs. chow
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(P = 0.000) and 13.59 % less AMPKα1 mRNA (P = 0.000)
transcripts than that in the DIO group.
Figure 2b shows that HF diet can suppress the protein
contents of LKB1 (P = 0.000), AMPKα1 (P = 0.019),
pAMPKα1 (P = 0.000), and pAMPKα2 (P = 0.000), and
increase the content of ACC (P = 0.005). The EA group
had 182.89 % higher LKB1 (P = 0.000), 135.42 % higher
pAMPKα1 (P = 0.002), and 84.27 % lower ACC (P =
0.003), 19.72 % lower AMPKα2 (P = 0.007) protein levels
than those in the DIO group.
Discussion
We observed that after 4 weeks of HF diet, nearly 50 %
of rats were obese. During the 4-week EA treatment, rats
in the EA group gained weight slower than those in the
DIO group starting in the third week. RT-PCR and west-
ern blotting showed that LKB1-AMPK signaling in the
hypothalamus is inhibited by HF diet, and ACC is sig-
nificantly upregulated. EA may upregulate transcriptionof AMPKα2, promote protein expression of LKB1 and
AMPKα1, and inhibit ACC protein expression to control
weight gain.
AMPK is widely expressed in neurons and astrocytes of
the hypothalamus and hindbrain, which are both areas in-
volved in food intake [21]. Under normal physiological
conditions, hypothalamic AMPK can be activated by infus-
ing 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside
(AICAR) into the third ventricle, which significantly in-
creases food intake [22]. Expressing dominant negative
AMPK in the hypothalamus can reduce food intake and
body weight [23].
Feeding mice a HF diet will cause dysregulation of AMPK
signaling pathway, which is associated with impaired
AMPK phosphorylation and downregulated protein expres-
sion in skeletal muscle, liver, and hypothalamus [24–27].
Under pathological conditions, a strong correlation be-
tween low activation state of AMPK and metabolic disor-
ders such as obesity, insulin resistance, and sedentary
activities has been established in a variety of rodent
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more sensitive to the deleterious effects of over-nutrition
[30]. Consistent with this hypothesis, whole-body ablation
of AMPKα2 activity exacerbates HF diet-induced obesity,
while the glucose disposal rates are similar to those of
wild-type mice [31].
As one of the most important regulators of energy bal-
ance, AMPK has close relationship with many metabolic-
related hormones, especially adipocytokines, such as lep-
tin, adiponectin and apelin. In physiology circumstance,
leptin [32] exerts an inhibitory effect on AMPK in the
hypothalamus by stimulating ACC and subsequently sup-
pressing food intake, meanwhile constitutive activation of
hypothalamic AMPK disrupts leptin’s anorexigenic effect.
In addition, inhibition of hypothalamic ACC attenuates
leptin-mediated inhibition in food intake and body
weight gain [33]. Latterly, it was shown that mTOR/
S6K regulates eating through leptin- mediated inhibition
of AMPK in the hypothalamus [34]. AMPK [35] signaling
also regulated adiponectin production by modulating the
expression of its receptors and itself. Apelin [36] is an adi-
pocytokine known for its anti-obesity and anti-diabetic
properties, Apelin promotes the expression of anti-
oxidant enzymes and suppresses the expression of pro-
oxidant enzyme via AMPK pathway.
Therefore, AMPK has emerged as a promising new
target for the treatment of metabolic disorders including
obesity, type 2 diabetes, and cardiovascular disease. Acti-
vation of AMPK using AICAR can increase glucose up-
take and fatty acid oxidation in obese diabetic rodents
[37, 38] and humans [39–43], which validates the thera-
peutic potential of an AMPK activator.
pAMPK is the activated state of AMPK, which is
phosphorylated on threonine residue 172 (Thr-172) in
the α subunit by upstream kinases like LKB1 [44]. The
combination of the allosteric and phosphorylation effects
causes a greater than 1000-fold increase in kinase activ-
ity (compared with less than 5-fold for allosteric activa-
tion alone). This response allows for high sensitivity in
responses to small changes in cellular energy status [45].
Activated AMPK catalyzes the dephosphorylation of
ACC, then increases the level of hypothalamic malonyl-
CoA which results in food intake suppression and an
eventual energy expenditure increase [46].
Our results demonstrate that EA rats had significantly
higher protein levels of LKB1 and pAMPKα1 compared
with DIO rats. Therefore, EA may promote the activity
of hypothalamic AMPK by increasing its phosphoryl-
ation level, and this effect may induced by an increase in
its upstream kinase, LKB1. Meanwhile, the decrease in
ACC protein level may be the result of AMPK activa-
tion. Alterations in the hypothalamic LKB1-AMPK-ACC
signaling pathway might contribute to the effect of EA
on slowing down weight gain in rats given an HF diet.However this hypothesis should be investigated further,
possibly with hypothalamic LKB1 and AMPK knock-
down rat models.
Intriguingly, we found significant weight differences
between the EA and DIO groups after 3 weeks and after
10 h fasting on the eighth week, but not on the eighth
week immediately after EA treatment. This is possibly
because acupuncture increases basal metabolic rate
(BMR) in the obese state [47]. SMR is the steady-state
rate of heat production by a whole organism under a set
of standard conditions. It is either measured directly as
heat production or indirectly as oxygen consumption.
The mainly contribution of the cellular processes that
underlie SMR includes a futile cycle of proton extrusion
across the mitochondrial inner membrane and the sub-
sequent proton leak back to the matrix via endogenous
proton conductance pathways, which accounted for
about one-half of the oxygen consumption rate of rest-
ing [48]. The proton leak is catalyzed by uncoupling pro-
teins (UCPs), UCP1, UCP2, and UCP3, and the classic
uncoupling protein is UCP1, which uncouples brown
adipose tissue (BAT) mitochondria causing facultative
thermogenesis [49]. When fully activated, UCP1 in BAT
can increase metabolic rate in rodents by fourfold [50].
Peroxisome proliferator-activated receptor gamma coac-
tivator 1α (PGC-1α) is a crucial activator of UCP1,
which induces the expression of the genes encoding for
UCP1 [51]. Increasing PGC-1α and UCP1 expressions
are considered to be treatment targets of obesity and
obesity-related diseases [52]. It is reported that EA can
upregulate PGC-1α mRNA (2–3-fold) to ameliorate in-
sulin resistance in obese and diabetic db/db mice [53].
Du H [54] found that EA effectively induces the mRNA
expression of PGC-1α and UCP-1 by 4-fold and 5-fold
in the BAT of obese rats, respectively. Shen WX [55]
found that UCP1 gene expression in white adipose tissue
(WAT) increased almost 14 folds in EA mice than in the
control mice, and the UCP1 protein expression also sig-
nificantly increased in EA mice. They presumed that EA
can remodel WAT to BAT by inducing UCP-1 expres-
sion, and this may be one of the mechanisms by which
acupuncture affects weight loss. Noteworthily, AMPK
can activates PGC-1α by phosphorylating on its specific
serine and threonine residues [56]. So EA may increase
BMR through AMPK - PGC-1α - UCP-1 pathway. Fur-
thermore, EA was found to increase small intestinal
transit. Acceleration of intestinal transit was found to be
associated with reduced absorption of nutrients [57].
Therefore, the accelerative effect of EA on intestinal
transit might contribute to reduced body weight [58].
Our body weight result is also confirmed by other re-
search [59]. It was reported that body mass reduction
was about two-fold greater in control versus high-fat
mice, possibly because fasting-induced responses occur
Xu et al. BMC Complementary and Alternative Medicine  (2015) 15:147 Page 7 of 9sooner in obese animals, especially decreases in VO2,
heat production, and nocturnal activity. Because of above
reasons, 10 h fasting enlarged weight differences between
EA and DIO group, then made it statistically significant.
This phenomenon may reflect sustainable effect of EA
treatment for obese and deserve further research.
We chose ST36 and ST25 as acupoints in this study
for a few reasons. Firstly, previous study showed that EA
treatment on these acupoints significantly reduced food
intake and body weight [60, 61]. Secondly, these two
acupoints are the most commonly used by others to
treat obesity either in animal studies or in clinical stud-
ies [62]. Third, stimulation of these acupoints was re-
ported to increase AMPK expression in some tissues
[18, 19]. However, a few reports showed that EA ST36
may enhanced appetite to a certain extent [63], but more
studies suggested that EA ST36 significantly inhibited
feeding and body weight gain [64–69]. The possible
mechanisms are down-regulated orexigenic peptides, such
as neuropeptide Y (NPY) [64], upregulates anorexigenic
hormones, including proopiomelanocortin (POMC) [65],
α-Melanocyte-stimulating hormone (α-MSH) [66], and
cholecystokinin (CCK) [67–69]. Nevertheless, there are
other acupoints used for the treatment of obesity, further
studies should test whether stimulation of other acupoints
acts through a similar mechanism like stimulation of ST36
and ST25.
Conclusions
Dysregulation of hypothalamic LKB1-AMPK-ACC sig-
naling was detected in DIO rats. EA treatment can in-
hibit weight gain in DIO rats fed an HF diet. RT-PCR
and western blotting showed that EA may act via upreg-
ulation of AMPKα2 transcription, promotion of LKB1
and AMPKα1 protein expression, and inhibition of ACC
protein expression to control energy balance. This study
suggests that hypothalamic LKB1-AMPK-ACC signaling
plays an important role in EA treatment for obesity.
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